louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00674726: Study on the Difference of Axilo-rectal Temperature in Appendicitis
Official title: Prospective Study on the Difference of Axilar-rectal Temperature in Acute Appendicitis
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Appendicitis
Gastroenteritis
Keywords: appendicitis
gastroenteritis
temperature
fever
acute abdomen
Axilo-rectal temperature in appendicitis
Axilo-rectal temperature in gastroenteritis
Lead sponsor: Cirujanos la Serena
Sponsor class: OTHER
First posted: 2008-05-08
Enrollment: 0
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients consulting in the emergency unit with acute appendicitis or acute gastroenteritis

Brief summary: The investigators are studying prospectively the difference in axilo-rectal temperature in patients with acute appendicitis and using as a control group patients consulting with acute gastroenteritis at our emergency unit.


Eligibility criteria: Inclusion Criteria:

* Patients with acute appendicitis
* Patients with acute gastroenteritis
* Patients older than 15 years of age

Exclusion Criteria:

* Other acute abdominal diseases

Primary outcomes:
measure: The real difference in axilo-rectal temperature in patients with acute appendicitis
timeFrame: 6 hours
Secondary outcomes:
measure: The differences in axilo-rectal temperature between patients with acute appendicitis and acute gastroenteritis
timeFrame: 6 hours
Other outcomes:
Locations:
city: La Serena
country: Chile
facility: Hospital de La Serena - Emergency Unit
state: IV Region
city: La Serena
country: Chile
facility: Hospital de La Serena
state: IV Region
Study officials:
affiliation: Hospital de La Serena
name: Marcelo A Beltran, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01268826: DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children
Official title: DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dehydration
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2010-12-31
Enrollment: 500
Sex: ALL
Minimum age (years): 9
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 500 children aged 9-11

Brief summary: The aim of the study is to determinate the prevalence of moderate dehydration among children aged 9 to 11 who are going to school.

Detailed description: Many children have a limited caloric intake at the breakfast with a limited amount of water intake. There is no data about the prevalence of dehydration in children who are regularly going to school in France.

Eligibility criteria: Inclusion Criteria:

* Healthy child aged 9 to 11 years old.

Exclusion Criteria:

* Individual with illness
* Individual with past history of gut or metabolic diseases
* Past history of renal disease.
* Child whom parents decline to participate

Primary outcomes:
measure: Prevalence of dehydration (as defined as urinary osmolality > 800 mOsmol/l) Osmolality is measured by freezing point depression
timeFrame: Day 1
Secondary outcomes:
measure: Amount of water intake at breakfast
timeFrame: Day 1
measure: Total energy and nutrient intake
timeFrame: Day 1
Other outcomes:
Locations:
city: Rennes
country: France
facility: Rennes University Hospital
Study officials:
affiliation: Rennes University Hospital
name: Fabrice Bonnet, MD, PU-PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04357626: Determinants of Rehabilitation Outcomes in Survivors of Primary Subarachnoid Haemorrhage
Official title: Determinants of Rehabilitation Outcomes in Survivors of Primary Subarachnoid
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Subarachnoid Hemorrhage, Spontaneous
Lead sponsor: Tan Tock Seng Hospital
Sponsor class: OTHER
First posted: 2020-04-22
Enrollment: 114
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients admitted acutely for inpatient rehabilitation from neurosurgical wards

Brief summary: A retrospective, observational single centre study of electronic medical records of discharged patients who were admitted to from 1 January 2015 to 31 December 2018.

Period of data collection was from 5 August 2019 to 15 September 2019.

Detailed description: The objectives of this study were to describe a local cohort of acute SAH survivors during inpatient rehabilitation at a single tertiary rehabilitation centre in Singapore and identify early predictors impacting discharge rehabilitation outcomes.

Eligibility criteria: Inclusion Criteria:

* 1. Spontaneous, first-ever SAH diagnosed by admitting neurosurgeons and confirmed on neuroimaging (CT or magnetic resonance imaging) 2. Transferred from acute care facilities or admitted from clinics to TTSH RC 3. Ages between 21 - 85 years 4. Duration of SAH to rehabilitation admission ≤6 months

Exclusion Criteria:

* 1. No radiological evidence of SAH 2. Traumatic SAH 3. Previous diagnosis of SAH 4. Main reason for admission into TTSH RC was not for inpatient rehabilitation (e.g. wound care, medical or social admission)

Primary outcomes:
measure: Functional Independence Measure (FIM score)
timeFrame: Within 72 hours of discharge from rehabilitation
Secondary outcomes:
measure: FIM Change
timeFrame: Within 72 hours of admission and discharge from rehabilitation
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Tan Tock Seng Hospital
city: Singapore
country: Singapore
facility: Tan Tock Seng Hospital Rehabilitation Centre
Study officials:
affiliation: Tan Tock Seng Hospital
name: Karen S Chua, MBBS FRCPE
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05967026: Characterization of Myocardial Infarction Scar Using Magnetic Resonance Imaging
Official title: Characterization of Myocardial Infarction Scar Using Magnetic Resonance Imaging
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Myocardial Infarction
Keywords: cardiac magnetic resonance
sudden cardiac death
risk stratification
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2023-08-01
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with a history of acute coronary syndrome prior to inclusion and having undergone cardiac MRI and LVEF \>35% measured at least 6 weeks post-IDM by echocardiography or MRI

Brief summary: The goal of this monocentric observationnal study is to describe the characteristics of the myocardial infarction scar in terms of transmurality in residual LVEF\>35% patients.

The primary objective is to determine the frequency of the criterion "intramural scar ≥1.47cm2" (measured by MRI) in patients who presented with myocardial infarction with residual LVEF≥35%.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years ;
* History of acute coronary syndrome prior to inclusion and having undergone cardiac MRI;
* LVEF \>35% measured at least 6 weeks post-IDM by echocardiography or MRI;

Exclusion Criteria:

- Patient with an implantable cardiac device (implantable cardioverter defibrillator or pacemaker) prior to MRI.

Primary outcomes:
measure: Intramural scar surface in cm²
timeFrame: 6 weeks after myocardial infarction
Secondary outcomes:
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHU of Nancy
Study officials:
References:
Clinical trial NCT03623126: Impact of ESSURE Devices Withdrawal on the Symptomatology of Patients
Official title: Impact of ESSURE Devices Withdrawal on the Symptomatology of Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Quality of Life
Contraceptive Device; Complications
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-08-09
Enrollment: 41
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who underwent ESSURE removal between January 2017 and January 2018 in the gynecology department of the Croix Rousse Hospital and the gynecology department of the Lyon Sud Hospital. .

Brief summary: The ESSURE device is a method of permanent contraception, marketed in France since 2005. Multiple side effects have been reported by patients since 2015 and the marketing was stopped in 2017. For several months it was observed an increase in requests for withdrawal of these devices. The principal objective of this study is to evaluate clinical improvement and quality of life after ESSURE removal.

This is a multicenter retrospective descriptive study involving the gynecology department of the Croix Rousse Hospital and the gynecology department of the Lyon Sud Hospital over a period of 1 year (1 January 2017-31 December 2017).


Eligibility criteria: Inclusion Criteria:

* Women who underwent ESSURE removal due to suspected adverse effects of the device.
* Women who agreed to participate in the study

Exclusion Criteria:

- Women who underwent ESSURE removal to restore their fertility.

Primary outcomes:
measure: Evaluation of the clinical improvement after the intervention of withdrawal of ESSURE devices
timeFrame: One day at least one month after the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Service de gynécologie-Obstétrique - Hôpital de la Croix Rousse
city: Pierre-Bénite
country: France
facility: Service de Gynécologie-Obstétrique - Centre Hospitalier Lyon Sud
Study officials:
References:
Clinical trial NCT00512226: Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
Official title: Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia Using T2* Cardiac MRI.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sickle Cell Anemia
Sickle Cell Thalassemia
Iron Overload
MRI
Keywords: Sickle Cell Anemia
Sickle Cell Thalassemia
Iron Overload
MRI
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
Collaborators: name: Wolfson Medical Center
First posted: 2007-08-07
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Iron overload is well study in Thalassemia patients and it's not only related to blood transfusions, since intestinal iron absorption is also increased in those patients. Sickle cell patients didn't develope significant clinical symptoms and signs of iron overload in spite frequent transfusions. The purpouse of this study is to assess the iron overload in Sickle cell anemia and Sickle cell Thalassemia patients using clinical parameters and cardiac T2\*MRI in order to determine the cardiac and liver iron.


Eligibility criteria: Inclusion Criteria:

* All the patients with Sickle cell anemia and Sickle cell Thalasemia that are currently in follow up at the Pediatric Hematology Unit

Exclusion Criteria:

* Age below 18 years.

Primary outcomes:
measure: Assessment of Iron overload.
timeFrame: December 2008
Secondary outcomes:
measure: Institute the criteria for iron chelator treatment
timeFrame: December 2008
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center
Study officials:
affiliation: Pediatric Hematology Unit, Ha'Emek Medical Center
name: Ariel Koren, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00718926: The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients
Official title: The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dry Eye Disease
Keywords: dry eye
Thiol redox
Oxidative stress
Lead sponsor: Meiji University of Oriental Medicine
Sponsor class: OTHER
Collaborators: name: Kyoto Prefectural University of Medicine
First posted: 2008-07-21
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Sampling method: PROBABILITY_SAMPLE
Study population: The dry eye patients at the clinic of Kyoto Prefectural University of Medicine hospital

Brief summary: Dry eye disease is related with oxidative stress at the ocular surface. GSH is one of the key factor of protect from oxidative stress. To evaluate thiol status of ocular surface cells by monitoring GSH concentration, we can evaluate the severity of dry eye.

Detailed description: The conjunctival cells are collected by impression cytology. Those cells are stained with 100 mM of monochlorobimane (MCB, M-1381, Molecular Probes, Eugene, OR) and propidium iodide (PI). Fluorescent intensity, reflecting the amount of icGSH, was inspected under a confocal laser scan microscope. To detect the GSH levels we used a fluorescent MCB probe with excitation and emission wavelengths of 405 nm and 410-480 nm, respectively. The cell-permeating MCB probe is non-fluorescent but forms a fluorescent adduct with GSH in a reaction catalyzed by glutathione-S-transferase.

Eligibility criteria: Inclusion Criteria:

* dry eye patients
* control volunteers

Exclusion Criteria:

* Young (less than 20) patients
* The patients who rejected this study

Primary outcomes:
measure: Tear amount, tear break up time, and so on are measured clinically. The thiol redox status is measured by staining the membrane.
timeFrame: Once a month (totally 2-4 times) at the clinic
Secondary outcomes:
Other outcomes:
Locations:
city: Kyoto
country: Japan
facility: Kyoto Prefectural University of Medicine hospital
Study officials:
References:
Clinical trial NCT00292526: Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
Official title: Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cardiotoxicity
Chemotherapeutic Toxicity
Keywords: Chemotherapy induced cardiotoxicity
Troponin
Heart failure
Lead sponsor: European Institute of Oncology
Sponsor class: OTHER
First posted: 2006-02-16
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.


Eligibility criteria: Inclusion Criteria:

* Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I

Exclusion Criteria:

* Contraindication to ACE-inhibitors
* On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers

Primary outcomes:
measure: Incidence of chemotherapy-induced cardiotoxicity
timeFrame: 12 month period
Secondary outcomes:
measure: Major adverse cardiac events, including death.
timeFrame: 12 month period
Other outcomes:
Locations:
city: Milan
country: Italy
facility: European Institute of Oncology
Study officials:
affiliation: European Institute of Oncology
name: Carlo M Cipolla, MD
role: STUDY_DIRECTOR
affiliation: European Institute of Oncology
name: Daniela Cardinale, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004 Jun 8;109(22):2749-54. doi: 10.1161/01.CIR.0000130926.51766.CC. Epub 2004 May 17.
citation: Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000 Aug;36(2):517-22. doi: 10.1016/s0735-1097(00)00748-8.
Clinical trial NCT05527626: Chronic Kidney Disease - REAL Life Study in Alsace
Official title: Chronic Kidney Disease - REAL Life Study in Alsace
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Kidney Diseases
Keywords: Kidney
Chronic Disease
Chronic Kidney Disease
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2022-09-02
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major subject (≥18 years) with a chronic renal disease

Brief summary: Chronic kidney disease (CKD) is a public health problem and affects about 10% of the world's adult population with a constantly increasing incidence. The approach to CKD in France is centered on access to replacement therapy (dialysis, renal transplantation), the cost of which amounts to 4 billion euros (data from the REIN registry).

Real-life data are essential to specify the characteristics of patients with chronic kidney disease and the factors associated with the evolution of CKD and the occurrence of complications in order to improve the management of CKD before the suppletion stage.

Since October 2019, CKD at the severe stage (stage 4) and at the non-dialysis end stage (stage 5) is subject to an annual flat fee (Article L. 162-22-6-2 of the Social Security Code). The reimbursement of these lump sums by the health insurance is subject to the collection and transmission of certain medical data by the establishments.


Eligibility criteria: Inclusion criteria:

* Major subject (≥18 years)
* Subject included in the MRC package (GFR \<30 ml/min/1.73 m2)
* Subject who has not expressed opposition, after information, to the reuse of his or her data for the purpose of this research

Exclusion criteria:

- Subject having expressed his opposition to participate in the study

Primary outcomes:
measure: Retroanalysis of the risk factors in patients with severe chronic kidney disease
timeFrame: Files analysed retrospectively from October 01, 2019 to February 31, 2027 will be examined
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service Néphrologie-Dialyse-Transplantation - CHU de Strasbourg - France
Study officials:
affiliation: Service Néphrologie-Dialyse-Transplantation - CHU de Strasbourg - France
name: Peggy PERRIN, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06984926: A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults
Official title: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 3810477 in Healthy Male and Female Trial Participants (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2025-05-22
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 3810477 in healthy male and female trial participants when given as multiple rising doses.


Eligibility criteria: Inclusion Criteria:

* Healthy male and female participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR), respiratory rate (RR), temperature), 12-lead electrocardiogram (ECG), and clinical laboratory tests.
* Age of 18 to 60 years (inclusive, to be checked at time of signing informed consent).
* BMI of 18.5 to 29.9 kg/m2 (inclusive).
* Signed and dated written informed consent in accordance with international conference on harmonization-good clinical practice (ICH-GCP) and local legislation prior to admission to the trial.
* Further inclusion criteria apply.

Exclusion Criteria:

* Any finding in the medical examination (including BP, PR, RR, temperature or ECG) deviating from normal and assessed as clinically relevant by the investigator.
* Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 100 beats per minute (bpm).
* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
* Any evidence of a concomitant disease assessed as clinically relevant by the investigator.
* Further exclusion criteria apply.

Primary outcomes:
measure: Occurrence of any treatment-emergent adverse events assessed as drug-related by the investigator
timeFrame: Up to Day 117
Secondary outcomes:
measure: Area under the concentration-time curve of BI 3810477 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
timeFrame: Up to Day 117
measure: Maximum measured concentration of BI 3810477 in plasma at steady state (Cmax,ss)
timeFrame: Up to Day 117
Other outcomes:
Locations:
Study officials:
References: